CMS Rebuffs OIG's Call To Add Pharmacy Names To Compounded Drug Claims but tells CMS can stop payments for drugs not produced under FDA requirements-Will this be another big blow to those in the compounding pharmacy worlds pocketbook?

CMS Rebuffs OIG's Call To Add Pharmacy Names To Compounded Drug Claims

Daily News

Wednesday, 30 April 2014

CMS rebuffed the HHS Office of Inspector General's suggestion that Medicare Part B claims for compounded drugs identify the firm producing the product, telling the OIG that CMS can stop payments for drugs not produced under FDA requirements but lacks methods to track or identify compounded drug claims.